eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

Rosemont Pharmaceuticals Limited
Rosemont House, Yorkdale Industrial Park, Braithwaite Street, Leeds, Yorkshire, LS11 9XE
Telephone: +44 (0)113 244 1400
Fax: +44 (0)113 246 0738
WWW: http://www.rosemontpharma.com
Customer Care direct line: +44 (0)800 919 312
Out of Hours Telephone: +44 (0)7836 557 879
Out of Hours contact: pharmacovigilance@rosemontpharma.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 05/10/2010
SPC Norzol 200mg/5ml Oral Suspension

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 05/10/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   24-Jun-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
In section 4.5 (Interaction with other medicinal products and other forms of interaction) busulfan  and busulfan toxicity has been added.

In section 10 (Date of Revision of the Text) the date has been updated to 24-June-2010.
Updated on 27/08/2008 and displayed until 05/10/2010
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 10 date of revision of the text
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 1 -Name of the Medicinal product
Date of revision of text on the SPC:   14-Apr-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Section 1: Name re-arranged    
Section 4.4: Excipient warnings updated as per legislation
Section 4.5: 5-fluorouracil and ciclosporin added
Section 4.7: Warnings re: drowsiness, dizziness, confusion, hallucinations, convulsions or transient visual disorders.
Section 4.8: Added oral mucositis, anorexia, erythema multiforme, abnormal liver function tests, cholestatic hepatitis, jaundice and pancreatitis, agranulocytosis, neutropaenia, thrombocytopaenia and pancytopaenia, pustular eruptions, myalgia, arthralgia and transient visual disorders, psychotic disorders, including confusion and hallucinations.
Updated on 21/09/2005 and displayed until 27/08/2008
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 6. 6 - Instruction for Use/Handling
  • Change to section 10 (date of (partial) revision of the text
Updated on 23/05/2003 and displayed until 21/09/2005
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change to section 2 - qualitative and quantitative composition
Updated on 26/09/2002 and displayed until 23/05/2003
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
  metronidazole benzoate